Acumen Pharmaceuticals Stock Fundamentals
| ABOS Stock | USD 1.65 0.04 2.48% |
Acumen Pharmaceuticals fundamentals help investors to digest information that contributes to Acumen Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Acumen Stock. The fundamental analysis module provides a way to measure Acumen Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acumen Pharmaceuticals stock.
At this time, Acumen Pharmaceuticals' Reconciled Depreciation is comparatively stable compared to the past year. Acumen | Select Account or Indicator |
Acumen Pharmaceuticals Company Shares Owned By Insiders Analysis
Acumen Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Acumen Pharmaceuticals Shares Owned By Insiders | 11.23 % |
Most of Acumen Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acumen Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 11.23% of Acumen Pharmaceuticals are shares owned by insiders. This is 26.02% lower than that of the Biotechnology sector and 20.8% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 11.3% lower than that of the firm.
Acumen Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Acumen Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Acumen Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Acumen Pharmaceuticals competition to find correlations between indicators driving Acumen Pharmaceuticals's intrinsic value. More Info.Acumen Pharmaceuticals is rated fourth in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, Acumen Pharmaceuticals' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Acumen Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Acumen Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acumen Pharmaceuticals' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acumen Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acumen Pharmaceuticals by comparing valuation metrics of similar companies.Acumen Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.
Acumen Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | (72.74 M) | ||||
| Shares Outstanding | 60.08 M | ||||
| Shares Owned By Insiders | 11.23 % | ||||
| Shares Owned By Institutions | 78.47 % | ||||
| Number Of Shares Shorted | 1.56 M | ||||
| Price To Book | 0.46 X | ||||
| Price To Sales | 538.78 X | ||||
| Gross Profit | (72.52 M) | ||||
| EBITDA | (51.61 M) | ||||
| Net Income | (52.37 M) | ||||
| Cash And Equivalents | 189.91 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 28.49 M | ||||
| Current Ratio | 37.21 X | ||||
| Book Value Per Share | 3.62 X | ||||
| Cash Flow From Operations | (43.06 M) | ||||
| Short Ratio | 3.92 X | ||||
| Earnings Per Share | (1.38) X | ||||
| Price To Earnings To Growth | (0.23) X | ||||
| Target Price | 10.8 | ||||
| Number Of Employees | 51 | ||||
| Beta | 0.039 | ||||
| Market Capitalization | 99.13 M | ||||
| Total Asset | 310.12 M | ||||
| Retained Earnings | (222.8 M) | ||||
| Working Capital | 233.64 M | ||||
| Net Asset | 310.12 M |
About Acumen Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acumen Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acumen Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acumen Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Cost Of Revenue | 48.7 M | 51.1 M | |
| Stock Based Compensation To Revenue | 0.10 | 0.08 | |
| Sales General And Administrative To Revenue | 0.85 | 0.59 | |
| Research And Ddevelopement To Revenue | 5.01 | 4.25 | |
| Revenue Per Share | 0.04 | 0.04 | |
| Ebit Per Revenue | (6.34) | (6.65) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.